The journal of allergy and clinical immunology: Foreword

Journal of Allergy and Clinical Immunology

Volumn 109, Issue , 2002, Pages S479-S481

  Boushey, Homer A ^a,c   Stempel, David A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VIRGINIA MASON MEDICAL CENTER   (United States)

^c DUPONT COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGY; ASTHMA; EDITORIAL; EVIDENCE BASED MEDICINE; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; ARTICLE; DISEASE MANAGEMENT;

ANTIASTHMATIC AGENT; ANTIINFLAMMATORY AGENT; STEROID;

ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; DISEASE MANAGEMENT; EVIDENCE-BASED MEDICINE; HUMANS; PRACTICE GUIDELINES; STEROIDS;

EID: 0036583217     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2002.122713     Document Type: Article

References (9)

1. Inhaled corticosteroids: Impact on asthma morbidity and mortality
2. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids
3. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid
4. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma
5. Effect of inhaled formoterol and budesonide on exacerbations of asthma
6. Worldwide trends in asthma mortality during the twentieth century
7. Inhaled corticosteroids plus salmeterol or montelukast: Effect on resource utilization and costs